Accéder au contenu
Merck
  • Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.

Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.

European journal of medicinal chemistry (2014-06-16)
Vivek K Vyas, Bhavesh Variya, Manjunath D Ghate
RÉSUMÉ

In continuation of our research for novel human dihydroorotate dehydrogenase (hDHODH) inhibitors, herein we reported design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives. Human DHODH enzyme inhibition assay was used to screen the synthesized compounds as hDHODH inhibitors. The synthesized compounds were also evaluated for their antiproliferative effects on the cancer cell lines (HEP-3B and A-375) to establish a proof as anticancer agents. The chemical structures of compounds were confirmed by (1)H, (13)C NMR, IR, MS and elemental analysis. The purity of compounds was also checked by HPLC analysis. Compounds with bulky groups (-OCH3, -OCF3 and -CF3) at C6-position of quinoline ring showed good activity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
2,6-Dichloroindophenol sodium salt hydrate, suitable for vitamin C determination, BioReagent
Sigma-Aldrich
Decylubiquinone, ≥97% (HPLC)
Sigma-Aldrich
Sodium 2,6-dichloroindophenolate hydrate, ACS reagent